Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
NuVasive Inc. released a report on its financial outlook, including reiterating its 2015 guidance in issuing preliminary 2016 figures, as well as announcing the opening of a new facility in West Carrollton, Ohio.
At its investor day, NuVasive released preliminary guidance for 2016, expecting revenue to grow to $870 and to see its non-GAAP operating profit margin to expand approximately 100 base points compared with 2015. Read more
Edwards Lifesciences took out a stake with an exclusive option to buy in Harpoon Medical potentially adding a mitral repair device to the mitral valve replacement being developed by recent acquisition CardiAQ Valve Technologies.
Irvine, Calif.-based Edwards did not reveal the size of its stake in Harpoon when it released new guidance earlier this week. Read more
Medtronic said that the FDA expanded the indication for its controversial InFuse bone-growth protein, allowing for its use with polyetheretherketone implants in oblique lateral interbody fusion and anterior lumbar interbody fusion surgeries.
The new indications cover single-level fusion OLIF51 procedures from the L5 vertebra to S1 with Medtronic’s PEEK Perimeter implant; OLIF25 fusions from L2 to L5 using the PEEK Clydesdale implant; and ALIF procedures from L2 to S1 using the Perimeter device, the company said. Read more